{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0010679,73,MONDO:0010679,199,0]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0010679","source":"MONDO:0010679|Duchenne muscular dystrophy","targets":["NCT00606775|The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00819845|Ramipril Versus Carvedilol in Duchenne and Becker Patients|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01422200|Flu Vaccine Study in Neuromuscular Patients 2011|COMPLETED|PHASE4|INTERVENTIONAL","NCT01999075|Stacking Exercises Aid the Decline in FVC and Sick Time|COMPLETED|PHASE4|INTERVENTIONAL","NCT04687020|Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)|ACTIVE_NOT_RECRUITING|PHASE4|INTERVENTIONAL","NCT04708314|An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy|TERMINATED|PHASE4|INTERVENTIONAL","NCT05412394|Once Weekly Infant Corticosteroid Trial for DMD|RECRUITING|PHASE4|INTERVENTIONAL","NCT06713135|A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy|ACTIVE_NOT_RECRUITING|PHASE4|INTERVENTIONAL","NCT00004646|Phase III Randomized, Double-Blind Study of Prednisone for Duchenne Muscular Dystrophy|COMPLETED|PHASE3|INTERVENTIONAL","NCT00016653|Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00018109|A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00110669|High-dose Prednisone in Duchenne Muscular Dystrophy|COMPLETED|PHASE3|INTERVENTIONAL","NCT00308113|CoQ10 and Prednisone in Non-Ambulatory DMD|TERMINATED|PHASE3|INTERVENTIONAL","NCT00839033|Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders|TERMINATED|PHASE3|INTERVENTIONAL","NCT01027884|Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01126697|Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT01183767|Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT01247207|Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)|ENROLLING_BY_INVITATION|PHASE3|INTERVENTIONAL","NCT01557400|Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada|COMPLETED|PHASE3|INTERVENTIONAL","NCT01603407|Finding the Optimum Regimen for Duchenne Muscular Dystrophy|COMPLETED|PHASE3|INTERVENTIONAL","NCT01648634|Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy|COMPLETED|PHASE3|INTERVENTIONAL","NCT01826487|Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01865084|A Study of Tadalafil for Duchenne Muscular Dystrophy|TERMINATED|PHASE3|INTERVENTIONAL","NCT02090959|An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy|TERMINATED|PHASE3|INTERVENTIONAL","NCT02255552|Study of Eteplirsen in DMD Patients|COMPLETED|PHASE3|INTERVENTIONAL","NCT02354352|Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy|COMPLETED|PHASE3|INTERVENTIONAL","NCT02500381|Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02814019|A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids|TERMINATED|PHASE3|INTERVENTIONAL","NCT02851797|Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy|COMPLETED|PHASE3|INTERVENTIONAL","NCT03039686|Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT03179631|Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy|COMPLETED|PHASE3|INTERVENTIONAL","NCT03354039|Tamoxifen in Duchenne Muscular Dystrophy|COMPLETED|PHASE3|INTERVENTIONAL","NCT03373968|Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT03532542|An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy|TERMINATED|PHASE3|INTERVENTIONAL","NCT03603288|Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)|TERMINATED|PHASE3|INTERVENTIONAL","NCT03642145|A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT03703882|Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy|COMPLETED|PHASE3|INTERVENTIONAL","NCT03779646|Bisoprolol in DMD Early Cardiomyopathy|UNKNOWN|PHASE2/PHASE3|INTERVENTIONAL","NCT03907072|Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy|TERMINATED|PHASE2/PHASE3|INTERVENTIONAL","NCT03917719|An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy|TERMINATED|PHASE3|INTERVENTIONAL","NCT03992430|A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04060199|Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)|COMPLETED|PHASE3|INTERVENTIONAL","NCT04281485|Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04371666|Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)|TERMINATED|PHASE3|INTERVENTIONAL","NCT04587908|A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD）|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04632940|Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD|TERMINATED|PHASE3|INTERVENTIONAL","NCT04768062|Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05066633|The Efficacy and Safety of Metoprolol as add-on Treatment to Standard of Care in Preventing Cardiomyopathy in Patients With DMD|RECRUITING|PHASE3|INTERVENTIONAL","NCT05096221|A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)|COMPLETED|PHASE3|INTERVENTIONAL","NCT05126758|A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05195775|Tadalafil as Adjuvant Therapy for DMD|ACTIVE_NOT_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT05689164|A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.|TERMINATED|PHASE3|INTERVENTIONAL","NCT05693142|AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT05881408|A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05933057|Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy|RECRUITING|PHASE3|INTERVENTIONAL","NCT05967351|A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study|ENROLLING_BY_INVITATION|PHASE3|INTERVENTIONAL","NCT07160634|A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)|RECRUITING|PHASE3|INTERVENTIONAL","NCT00033189|An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy|COMPLETED|PHASE2|INTERVENTIONAL","NCT00033813|KUL0401: An Open-label Pilot Study of Oxatomide in Steroid-Naive Duchenne Muscular Dystrophy|COMPLETED|PHASE2|INTERVENTIONAL","NCT00102453|Pentoxifylline in Duchenne Muscular Dystrophy|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00159250|Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00243789|Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00264888|Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy|COMPLETED|PHASE2|INTERVENTIONAL","NCT00296621|Effect of Oral Glutamine on Muscle Mass and Function in Duchenne Muscular Dystrophy|COMPLETED|PHASE2|INTERVENTIONAL","NCT00592553|Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)|COMPLETED|PHASE2|INTERVENTIONAL","NCT00654784|Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy|COMPLETED|PHASE2|INTERVENTIONAL","NCT00758225|Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)|COMPLETED|PHASE2|INTERVENTIONAL","NCT00759876|Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)|TERMINATED|PHASE2|INTERVENTIONAL","NCT00844597|Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00847379|Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)|TERMINATED|PHASE2|INTERVENTIONAL","NCT01009294|Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)|TERMINATED|PHASE2|INTERVENTIONAL","NCT01037309|Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD)|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT01099761|Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy|TERMINATED|PHASE2|INTERVENTIONAL","NCT01168908|Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy|TERMINATED|PHASE2|INTERVENTIONAL","NCT01207908|Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT01239758|Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy|TERMINATED|PHASE2|INTERVENTIONAL","NCT01396239|Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients|COMPLETED|PHASE2|INTERVENTIONAL","NCT01540409|Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy|COMPLETED|PHASE2|INTERVENTIONAL","NCT01540604|CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers|COMPLETED|PHASE2|INTERVENTIONAL","NCT01610440|Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy|UNKNOWN|PHASE1/PHASE2|INTERVENTIONAL","NCT01761292|A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT01826474|Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT01834040|Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy|UNKNOWN|PHASE1/PHASE2|INTERVENTIONAL","NCT01847573|Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT01918384|Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy|UNKNOWN|PHASE2|INTERVENTIONAL","NCT01957059|A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT01978366|Open Label Extension Study of HT-100 in Patients With DMD|TERMINATED|PHASE2|INTERVENTIONAL","NCT02036463|A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy|WITHDRAWN|PHASE2|INTERVENTIONAL","NCT02167217|Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy|COMPLETED|PHASE2|INTERVENTIONAL","NCT02196467|Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) Patients|UNKNOWN|PHASE1/PHASE2|INTERVENTIONAL","NCT02285673|Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy|UNKNOWN|PHASE1/PHASE2|INTERVENTIONAL","NCT02286947|Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy|COMPLETED|PHASE2|INTERVENTIONAL","NCT02310763|A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy|TERMINATED|PHASE2|INTERVENTIONAL","NCT02310906|Phase I/II Study of SRP-4053 in DMD Patients|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT02329769|Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)|TERMINATED|PHASE2|INTERVENTIONAL","NCT02354781|Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT02420379|Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy|COMPLETED|PHASE2|INTERVENTIONAL","NCT02439216|Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT02485938|HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)|COMPLETED|PHASE2|INTERVENTIONAL","NCT02525302|HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02|TERMINATED|PHASE2|INTERVENTIONAL"]}]}